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Abstract
Background: The use of chemotherapy regimens with moderate or high risk of febrile neutropenia (defined as
having a FN incidence of 10% or more) and the respective incidence and clinical management of FN in breast
cancer and NHL has not been studied in Belgium. The existence of a medical need for G-CSF primary and
secondary prophylaxis with these regimens was investigated in a real-life setting.
Methods: Nine oncologists and six hematologists from different Belgian general hospitals and university centers
were surveyed to collect expert opinion and real-life data (year 2007) on the use of chemotherapy regimens with
moderate or high risk of febrile neutropenia and the clinical management of FN in patients aged <65 years with
breast cancer or NHL. Data were retrospectively obtained, over a 6-month observation period.
Results: The most frequently used regimens in breast cancer patients (n = 161) were FEC (45%), FEC-T (37%) and
docetaxel alone (6%). In NHL patients (n = 39), R-CHOP-21 (33%) and R-ACVBP-14 (15%) were mainly used. Without
G-CSF primary prophylaxis (PP), FN occurred in 31% of breast cancer patients, and 13% had PSN. After G-CSF
secondary prophylaxis (SP), 4% experienced further FN events. Only 1 breast cancer patient received PP, and did
not experience a severe neutropenic event. Overall, 30% of chemotherapy cycles observed in breast cancer
patients were protected by PP/SP. In 10 NHL patients receiving PP, 2 (20%) developed FN, whereas 13 (45%) of the
29 patients without PP developed FN and 3 (10%) PSN. Overall, 55% of chemotherapy cycles observed in NHL
patients were protected by PP/SP. Impaired chemotherapy delivery (timing and/or dose) was reported in 40%
(breast cancer) and 38% (NHL) of patients developing FN. Based on oncologist expert opinion, hospitalization rates
for FN (average length of stay) without and with PP were, respectively, 48% (4.2 days) and 19% (1.5 days). Similar
rates were obtained from hematologists.
Conclusions: Despite the studied chemotherapy regimens being known to be associated with a moderate or high
risk of FN, upfront G-CSF prophylaxis was rarely used. The observed incidence of severe neutropenic events
without G-CSF prophylaxis was higher than generally reported in the literature. The impact on medical resources
used is sizeable.
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Background
Severe neutropenic events are life-threatening conditions
that can lead to serious infection, long-lasting hospitali-
zation and death, on top of being a dose-limiting toxi-
city of cancer chemotherapy. A retrospective analysis of
a 1999 hospital discharge database, which included data
from seven states in the USA, reported a mortality rate
of 6.8% for patients hospitalized for FN, equating to one
death for every 14 hospitalized patients [1]. In another
study, the reported overall in-hospital mortality with FN
was 9.5% [2], while a recent claims database study
showed a significant increase in the risk of overall and
early mortality in patients with FN compared to controls
by 15% and 35% respectively [3]. Moreover, severe neu-
tropenia often leads to a delay or dose reduction in
planned chemotherapy [4,5] and has been shown to
negatively influence patient quality of life [6,7].
Several randomized controlled trials demonstrated a
significant reduction in FN after systemic chemotherapy
with the use of prophylactic G-CSF compared with
untreated controls, and a recent meta-analysis on the
proactive use of G-CSF as primary prophylaxis revealed
a significant reduction in the risk of FN (RR = 0.54) and
infection-related mortality (RR = 0.55) with this strategy,
together with a significant increase in the relative dose
intensity of the chemotherapy administered (+8.4% on
average) [8]. A US claims database study confirmed the
use of G-CSF prophylaxis to significantly reduce the
hazard of overall mortality (HR = 0.65 [0.53; 0.79]) [3].
Conversely, the absence of G-CSF prophylaxis was sig-
nificantly associated with higher rate of FN and reduced
relative dose-intensity in NHL patients from two retro-
spective studies [9,10]. Other studies, in both clinical
trial and community settings, have demonstrated that
FN events mainly occur during the first cycles of che-
motherapy, thereby highlighting the importance of pri-
mary prophylaxis in patients at high risk for FN [11-14].
International guidelines concerning the use of G-CSF
have been issued by professional cancer associations
such as ASCO, EORTC, ESMO and NCCN [15-17].
According to these guidelines, a patient’s overall risk
for FN is comprised of two components: the type of
chemotherapy itself and patient-related factors such as
age, performance status and comorbidities. Taking these
factors into account, patients can be allocated to one of
three FN risk groups: low risk (< 10%), intermediate risk
(10-20%) and high-risk (≥20%). All guidelines make
similar recommendations regarding the use of G-CSF as
primary prophylaxis in patients with an overall high risk
of FN (e.g. ≥ 20%).
Both the EORTC and ASCO guidelines present
good evidence that prophylactic G-CSF decreases the
incidence of dose reductions and delays, and advocate
the use of primary prophylaxis to maintain the
intended dose intensity of chemotherapy when survi-
val benefits are expected, such as in patients with
breast cancer or NHL.
Although clinical studies have demonstrated the risk
of FN for several chemotherapy regimens in a clinical
study setting, few attempts have been made to describe
the occurrence of FN in real-life settings beyond the
strict context of a clinical trial [18,19]. Likewise,
although international guidelines are clear on the use of
G-CSF prophylaxis, data on the use of G-CSF for FN
prophylaxis in real-life practice are scarce.
In Belgium, access to a specific therapy is largely
dependent on the reimbursement criteria centrally regu-
lated by the Social Security Authority (RIZIV-INAMI),
and no data have been published on the actual use of
G-CSF in different patient settings in Belgium. During
the period of our study, patients with breast cancer or
NHL younger than 65 years of age were eligible for the
reimbursement of G-CSF as prophylaxis only when used
as secondary prevention (’reactive’ use). It is therefore
expected that the use of G-CSF for primary prevention
will be rather limited in these patients. The primary
objective of this survey was therefore to obtain real-life
data on the use of chemotherapy regimens documented
in clinical trials to provide a moderate or high risk of
FN (incidence >= 10%), including the observed inci-
dence of FN in daily practice. A secondary objective was
to obtain expert opinion on the current management of
FN in a Belgian clinical setting. It was anticipated that
the survey outcome would contribute to a re-evaluation
of the medical need for G-CSF prophylaxis with the use
of these regimens in these specific types of patients, and
provide basic data with which to analyze the budgetary
implications of a potential enlargement of the Belgian
reimbursement criteria.
Methods
The study was designed as a written expert survey. Two
similar but separate surveys were conducted, one invol-
ving a panel of oncologists (indication breast cancer)
and one involving hematologists (indication NHL).
Experts from both general hospitals and university cen-
ters were included.
Two documents were completed by each investigator.
The first document comprised a spreadsheet for the
collection of retrospective individual patient data from
patient files or departmental databases. This patient-
level information was automatically summarized per
chemotherapy regimen on a separate spreadsheet,
providing aggregated numbers only. The second docu-
ment comprised a written questionnaire which asked
the investigator about his/her daily practice relating to
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G-CSF prophylactic use and FN management (and
hence was not based on real patient data).
Definitions
Definitions of primary and secondary G-CSF prophylaxis
were provided in the survey protocol sent to all partici-
pating centers. Primary G-CSF prophylaxis (PP) was
defined as the administration of G-CSF from the first
cycle of chemotherapy and for subsequent cycles. Two
types of secondary prophylaxis (SP) were distinguished,
driven by the first neutropenic event: administration of
G-CSF in the cycles following the occurrence of FN
(SP-FN) and administration of G-CSF following the
occurrence of PSN (SP-PSN) during a chemotherapy
cycle. In the current paper, a severe neutropenic event
refers to either FN or PSN (defined as an episode of
severe neutropenia grade 4, without fever, for ≥ 5 days).
Real patient-based information: patient selection
Data on patients aged < 65 years and treated with a
cytotoxic chemotherapy regimen for breast cancer or
aggressive NHL in the investigator’s department
between 01 April 2007 and 30 September 2007 (recruit-
ment period) were included. Each investigator enrolled a
maximum of 25 breast cancer or 15 NHL patients, and
included the most recently and consecutively treated
patients. The FN risk of chemotherapy regimens was
assessed according to EORTC guidelines, by type of
malignancy.
For each eligible patient, the observation period
started on the first cycle of the chemotherapy regimen
administered at recruitment and stopped after 6 months,
or earlier in case of death, loss-to-follow-up or if
switched to another protocol. This duration of 6 months
was chosen in order to capture at least 6-8 chemother-
apy cycles of 28, 21 or 14 days’ duration.
Real patient-based information: variables collected
The investigator was asked to provide the following
information per patient: age, prior FN (yes/no), prior/
concomitant radiotherapy (yes/no), use of G-CSF pro-
phylaxis for FN (yes/no), name of the chemotherapy
regimen received, number of cycles observed, occur-
rence of FN during the observation period (yes/no) and
consequences of FN on the chemotherapy (dose adjust-
ment, delay, cycles dropped, switch to another regimen).
Information collected that was specific to breast can-
cer included: disease stage (early/locally advanced or
metastatic), presence of bone metastasis (yes/no) and
prior/concomitant surgery or hormone therapy (yes/
no). Information specific to NHL included: Interna-
tional Prognosis Index (IPI) and the Ann Arbor classi-
fication [20,21].
Information retrieved as expert opinion
Variables collected in the expert survey included center
location, number of beds, usage of chemotherapy regi-
mens with moderate or high risk of FN (from a prede-
termined list of regimens or possibly institution-based
regimens), G-CSF primary or secondary prophylaxis
(proportional use by drug, dosage, duration) and clinical
management of FN (type and frequency of medications,
procedures, hospitalizations, length of stay with or with-
out G-CSF prophylaxis).
Statistical analysis
The analysis was descriptive. The primary objective of
the study was to estimate the proportional use of che-
motherapy regimens carrying a moderate or high risk of
FN in patients with breast cancer or NHL.
As part of the secondary objectives, the study sample
was described in terms of real-life occurrence of neutro-
penic events (FN/PSN), presence of G-CSF prophylaxis
and consequences of FN on the chemotherapy protocol
(percentage of patients who experienced dose adjust-
ment or delay, dropped cycles or were switched to
another regimen as a result of developing FN). Results
were presented by indication and by regimen subgroups
where sample size allowed.
Finally, information from experts on the type of
G-CSF used and the clinical management of FN was
summarized using descriptive statistics, based on the
average of investigators’ answers.
Results
In total, nine oncologists and six hematologists spread
regionally (eight from the south and five from the north
of Belgium, two from Brussels) and representing univer-
sity (seven) and general (eight) hospitals contributed
data to both parts of the survey. The participation rate
was 45% in both indications. Real-life data were col-
lected for 161 breast cancer (969 cycles of chemotherapy
observed) and 39 NHL patients (208 cycles).
Breast cancer patients - characteristics and proportional
use of chemotherapy regimens
The 161 breast cancer patients were aged between 21
and 65 years; 88% had early/locally advanced disease
and 12% had metastatic disease (7% with bone metasta-
sis). A majority of women had already been treated with
surgery (90%), radiotherapy (69%) and/or hormone ther-
apy (56%). Only two patients (1%) had experienced a
prior FN episode.
The three most frequently used regimens associated
with a moderate or high risk of FN used in breast can-
cer were: FEC (45%), FEC-T (3 or 4 cycles each, 37%)
and docetaxel alone (6%). Other regimens with a
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moderate risk of FN were used in only one or two
breast cancer patients (Table 1).
Use of G-CSF in FN prophylaxis (breast cancer patients)
Only 1 of the 161 patients with breast cancer (<1%)
received PP, whereas 67 (42%) patients received SP (SP-
PSN in 12% and SP-FN in 29%) (Table 2). In total, 30%
of the 969 observed chemotherapy cycles were sup-
ported by G-CSF prophylaxis. The mean cycle number
on which SP was started was 2.1 following PSN and 3.4
following FN, meaning that a first severe neutropenic
event occurred mainly in cycle 1 or cycle 2 (Table 2).
Of note, three patients with breast cancer developed FN
during the last chemotherapy cycle and therefore did
not receive SP-FN (see in Table 2, 50 patients develop-
ing FN, and only 47 patients receiving SP-FN).
Real-life occurrence of neutropenic events (breast cancer
patients)
In the 160 patients not receiving PP, 44% developed a
severe neutropenic event (50 patients [31%] developed
FN and 20 [13%] PSN) - 49% of those receiving FEC,
42% receiving FEC-T and 33% receiving docetaxel. Only
three patients had further episodes of FN (4% of 68
patients with cycles protected) after SP was implemen-
ted (Table 2).
Consequences of FN on treatment of breast cancer
patients
The consequences of an FN episode in the 50 patients
experiencing FN were dose adjustment in 12 breast
cancer patients (24% of patients who developed FN),
dose delays in 12 patients (24%), cycle dropped in
8 patients (16%) and a switch to another regimen in
6 patients (12%) (Table 2). Overall, 20 (40%) patients
developing FN experienced at least one of the above-
mentioned impairments to their treatments, of whom
17 were treated with the three most frequently used
regimens.
NHL patients characteristics and proportional use of
chemotherapy regimens
Thirty-nine NHL patients aged between 18 and 64 years
were analyzed. A majority showed the involvement of
one or more extralymphatic organs (62% with Ann Arbor
stage IV). IPI was low in 28%, low/intermediate in 36%,
high/intermediate in 15% and high in 21% of patients. No
prior FN was reported. Prior/concomitant radiotherapy
was received by 5% of patients (see Table 3).
A wide range of regimens with moderate or high risk of
FN was used to treat aggressive NHL. The most frequently
used regimens in our sample were R-CHOP-21 (in 33% of
patients), R-ACVBP-14 (15%) and CHOP-21 (8%).
Use of G-CSF in FN prophylaxis (NHL patients)
G-CSF was administered to 10 (26%) patients as PP and
to 16 (41%) as SP (8% after PSN and 33% after FN). The
mean cycle number at which SP was started was 2.0 fol-
lowing PSN and 2.7 following FN, meaning that major
neutropenic events occurred mainly during the first che-
motherapy cycle (see Table 2). One patient developed a
FN episode in the last chemotherapy cycle and therefore
did not receive SP-FN. Of 11 patients with NHL treated
with a dose-dense chemotherapy only three (27%)
received PP.
Real-life occurrence of neutropenic events in NHL
patients
Overall, FN occurred in 16 patients (41%) and PSN in
another 3 patients (8%). Among the 10 patients receiv-
ing PP, 2 (20%) developed FN. Among the 29 patients
not receiving PP, 14 (48%) developed FN and another 3
(10%) experienced PSN; 16 patients (41%) subsequently
received SP.
In the 26 patients with at least 1 protected cycle, 8
(31%) experienced at least one new episode of FN in the
further course of their treatment (Table 2). Among the
11 NHL patients receiving dose-dense chemotherapy, 3
patients (27%) received PP and 7 (64%) received SP. The
Table 1 Basic characteristics of breast cancer patients from the study sample
Basic demographic & clinical characteristics FEC (n = 73) FEC-T (n = 60) All regimens (n = 161) a
Age range (years) 28-63 27-65 21-65
Disease stage, n (%) metastatic 12 (16) 1 (2) 20 (12)
Bone metastasis, n (%) 7 (10) 0 (0) 12 (7)
HER status, n (%) positive 17 (23) 25 (42) 53 (33)
Prior/concomitant surgery, n (%) 67 (92) 53 (88) 145 (90)
Prior/concomitant radiotherapy, n (%) 49 (67) 40 (67) 111 (69)
Prior/concomitant hormone therapy, n (%) 42 (58) 33 (55) 90 (56)
Basic demographic and clinical characteristics of the breast cancer patients are presented for the two most frequent chemotherapy regimens, and all regimens.
aOther regimens used in the sample but not displayed were docetaxel (n = 9), AC ® T (n = 5), capecitabine/docetaxel (n = 2), capecitabine/docetaxel/
trastuzumab (n = 2), docetaxel/trastuzumab (n = 2), epirubicin/cyclophosphamide (n = 2), FEC/trastuzumab (n = 2) and capecitabine/larotaxel, doxorubicin/
docetaxel, epirubicin/docetaxel, epirubicin/cyclophosphamide/larotaxel (1 patient each)
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Table 2 Description of G-CSF use and occurrence of neutropenic events in study sample (breast cancer and NHL
patients)
Breast cancer regimens NHL regimens
Outcome FEC
(n = 73)
FEC-T
(n = 60)
All
(n = 161)
Dose-dense
(n = 11)
All
(n = 39)
Patients with G-CSF use n (%) n (%) n (%) n (%) n (%)
Primary prophylaxis (PP) 0 1 (2) 1 (<1) 3 (27) 10 (26)
Secondary prophylaxis (SP) 36 (49) 23 (38) 67 (42) 7 (64) 16 (41)
due to FN (SP-FN) 23 (32) 17 (28) 47 (29) 6 (55) 13 (33)
Total patients developing FNa 23 (32) 19 (32) 50 (31) 7 (64) 16 (41)
Cycle # to start SPb Mean cycle # Mean cycle # Mean cycle # Mean cycle # Mean cycle #
After FN 3.2 3.4 3.4 2.5 2.7
After PSN 2.1 2 2.1 2.0 2.0
Total number of cycles observed 424 402 969 49 208
Cycles protected by G-CSF (% observed cycles) 145 (34) 103 (26) 287 (30) 36 (73) 114 (55)
Neutropenic events by presence of PP/SP
N patients with at least one unprotected cycle 73 59 160 8 29
N (%) patients with event in unprotected cycles (first event only) 36 (49) 25 (42) 70 (44) 7 (88) 17 (58)
Of which FN 23 (32) 19 (32) 50 (31) 6 (75) 14 (48)
N patients with at least one protected cycle 36 24 68 10 26
N (%) patients with event in protected cycles 2 (6) 0 3 (4) 1 (10) 8 (31)
after PP NA 0 0 1 (10) 2 (8)
after SP 2 (6) 0 3 (4) 0 6 (23)
Impact of FN on chemotherapy delivery (N patients and % among those
who developed FN)
Dose adjustment 4 (17) 4 (21) 12 (24) 0 0
Dose delay 5 (22) 3 (16) 12 (24) 3 (43) 6 (38)
At least 1 cycle dropped 2 (9) 5 (26) 8 (16) 0 0
Switch chemotherapy protocol 3 (13) 2 (11) 6 (12) 0 0
Any type 8 (35) 8 (42) 20 (40) 3 (43) 6 (38)
This table summarizes, for different subgroups of chemotherapy regimens, the number of patients receiving each type of G-CSF prophylaxis, and the number of
patients experiencing severe neutropenic events, depending on the presence of protected/unprotected cycles. The consequences of FN on the chemotherapy
delivery are also presented.
aPatients who developed FN at the last cycle did not receive SP-FN.
bIf FN in cycle n, SP starts in cycle (n + 1).
NA: not applicable.
Table 3 Basic characteristics of patients with NHL from the study sample
Basic demographic & clinical characteristics 3-weekly regimens
(n=28)a
Dose dense regimens
(n=11)b
All regimens
(n=39)
Age range (years) 18-64 20-61 18-64
IPI low, n (%) 7 (25) 4 (36) 11 (28)
IPI low/intermediate, n (%) 11 (39) 3 (27) 14 (36)
IPI high/intermediate, n (%) 5 (18) 1 (9) 6 (15)
IPI high, n (%) 5 (18) 3 (27) 8 (21)
Ann Arbor stade III/IV, n (%) 21 (75) 8 (73) 29 (74)
Prior/concomitant radiotherapy, n (%) 2 (7) 0 2 (5)
Basic demographic and clinical characteristics of the patients with NHL are presented for all 3-weekly chemotherapy regimens, for dose-dense regimens (R-
ACVBP-14, ACVBP, R-CHOP-14 and R-etoposide, cyclophosphamide), and for all regimens.
a 3-weekly regimens were R-CHOP-21 (n = 13), CHOP-21 (n = 3), BVAM (n = 2), R-DHAP (n = 2), R-GEMOX (n = 2), R-COPADEM (n = 2) and Hyper CVAD, ESHAP,
methotrexate/vincristine/ifosfamide/dexamethasone, R-ICE (1 patient each).
b Dose-dense regimens were R-ACVBP-14 (n = 6), ACVBP (n = 2), R-CHOP-14 (n = 2) and R-etoposide-cyclophosphamide (n = 1).
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rate of FN occurring in protected cycles was 10% (1 FN
in a patient receiving PP), while the FN rate in unpro-
tected cycles was 75% (6 FN in the 8 patients with at
least 1 unprotected cycle).
Consequences of FN on treatment of NHL patients
Among the 16 patients who developed FN, 6 (38%)
experienced a delay in at least one chemotherapy cycle,
but there were no dose adjustments, dropped cycles or
switches due to FN (Table 2).
Expert opinion on prophylaxis and clinical management
of FN
On average, the oncologists stated that pegfilgrastim is
the drug they most frequently prescribe for PP (to 78%
of patients), followed by filgrastim (15%) and lenogras-
tim (7%). Pegfilgrastim is also the drug they most fre-
quently use for SP (in 84% of patients compared with
15% for filgrastim and 1% for lenograstim).
The oncologists surveyed use a variety of antibiotics in
patients who develop FN (Table 4), alone or in combi-
nation: piperacillin + tazobactam is the most frequently
used antibiotic (used in 34% of patients, on average), fol-
lowed by amikacin (26%) and ceftazidime (18%).
The medical procedures most frequently performed by
oncologists in cases of FN are chest X-ray (in 80% of
patients, on average), microbiological tests (78%) and
echography of the abdomen (7%).
Finally, oncologists estimated the hospitalization rate
due to FN at 48% in patients not receiving any type of
G-CSF prophylaxis (average length of stay 4.2 days)
compared with 19% in patients receiving PP (1.5 days)
and 20% in patients receiving SP (3.3 days) (Table 4).
The clinical management of FN reported by hematolo-
gists for patients with NHL was overall similar to that
reported by oncologists for patients with breast cancer.
On average, the hematologists gave however a slightly
longer length of hospital stay for FN in NHL patients
not receiving G-CSF prophylaxis (5.6 days).
Discussion
This survey was initiated to collect recent Belgian data
on the use of chemotherapy regimens known to be asso-
ciated with a moderate or high risk of FN in breast can-
cer and aggressive NHL, and to capture data on the
occurrence and management of FN with these regimens
in current clinical practice.
The main survey interest is to provide new and usable
insights into the use of moderate or high risk regimens
in breast cancer and NHL, as well as on the incidence
and management of FN in these patient groups in a
Belgian daily practice setting.
A summary of the survey results is presented in Figure
1. The first observation to be made is that the overall
incidence of FN with the regimens investigated was
higher than that which would be expected from the
Table 4 Clinical management of FN based on expert opinion
Drug name Patients treated among those developing FN (%)a Total daily dose (mg) Average duration (days)
Piperacillin + tazobactam 34% 16 000 6.1
Amikacin 26% 1 000 to 1 500 4.1
Ceftazidime 18% 2 625 to 4 000 5
Amoxycillin + clavulanic acid 17% 6 000 5.4
Cefepime 14% 6 000 to 16 000 5.8
Filgrastim 13% 0.3 4.5
Fluconazole 8% 200 to 400 6.5
Ciprofloxacin 7% 0.3 5.5
Procedure name Patients treated among those developing FN (%)* Average frequency of procedure
Chest X-ray 80% 1.2
Microbiological tests 78% 2.4
Abdominal echography 7% 1.0
Hospitalization by usage of PP/SP Patients hospitalized among those developing FN (%) Average [range] LOS (days)
No G-CSF prophylaxis 48% 4.2 [3-7]
PP 19% 1.5 [1-2]
SP 20% 3.3 [3-7]
Only resources with frequencies >5% are reported. The table is based on oncologists’ answers. The participating hematologists reported similar findings (results
not shown).
LOS: length of stay.
aObtained by multiplying the percentage of experts mentioning the drug/test by the average proportion of patients receiving this drug/test as estimated by
these experts.
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literature, particularly in cycles not protected by G-CSF
prophylaxis (31% of breast cancer patients and 48% of
NHL patients had FN in unprotected cycles). Further-
more, these results appear to confirm, in a real-life set-
ting, the efficacy of secondary G-CSF prophylaxis in
limiting the occurrence of further FN and PSN, as it
was demonstrated in clinical trials [8]. We observed a
clear trend for patients with NHL to be at higher risk of
neutropenic complications than their breast cancer
counterparts (very probably due to more intensive che-
motherapy regimens).
In terms of the consequences of FN, 40% of breast
cancer patients who developed FN experienced some
chemotherapy dose reductions, dropped or delayed
cycles, whereas 38% of patients with NHL who devel-
oped FN experienced delays in cycles.
The observations from our study can be compared
with some results of recently published European stu-
dies in breast and NHL patients.
A prospective observational study investigated FN-
related endpoints such as occurrence of neutropenic
events, dose/delays issues, G-CSF protective effect and
FN treatment burden in breast cancer and lymphoma
patients in Europe (INC-EU study) [5].
Despite targeting similar endpoints, differences in
patient selection make comparison of the results difficult.
Indeed, all chemotherapy regimens used were eligible,
whereas in our study only regimens categorized as having
a moderate or high risk of FN were targeted. As a conse-
quence, a lower rate of neutropenic events was observed
in the INC-EU study as compared to the results reported
in our study: FN occurred respectively in 6% vs 31% of
breast cancer patients and in 22% vs 41% of NHL
patients. The use of primary prophylaxis was observed in
9% vs. only 1 patient (<1% of our sample) in breast can-
cer and in 28% vs 26% of patients in NHL patients. In
addition, a protective effect of primary G-CSF prophy-
laxis regarding cycle 1 FN occurrence and relative-dose
intensity was demonstrated via statistical modeling [18].
Also, significantly more dose delays and reductions
occurred in patients with FN (breast cancer: 42% with
delays, 39% with reduced dose; NHL: 53% and 40%)
compared to patients without neutropenic complication,
and these limitations occurred in proportions that are in
line with our assessment (40% of patients with FN
experiencing any type of impairment). Our study how-
ever failed to collect dose-limitation data for the patients
without FN (see limitations due to survey design below).
Figure 1 Tree-like representation of sample-based survey results in breast cancer and NHL. For each indication, the total number of
patients by type of G-CSF prophylaxis received and occurrence of FN/PSN is given under the corresponding branch
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The second study is a randomized controlled trial by
the Dutch/Belgian HOVON group, conducted in elderly
patients aged 65 and above with aggressive NHL, being
randomly assigned to receive either CHOP or CHOP
+G-CSF [22]. Although this patient group differs signifi-
cantly from our sample of younger patients (<65) trea-
ted with a variety of intense regimens, the reported
incidence of FN in this HOVON study is the same as
what we observed in our study, namely 41% of patients
developing FN (158 out of 389 patients in the HOVON
study and 16 out of 39 patients in our study). Despite
an only modest difference in FN rates between both
arms (37% in CHOP vs. 45% in CHOP+G-CSF), patients
with upfront G-CSF prophylaxis received a significantly
higher median relative dose intensity of cyclophospha-
mide (+2.4%) and doxorubicin (+2.1%), and experienced
significantly fewer cumulative days with antibiotics
(median 0 vs. 6 days).
The latter outcome regarding medical resource use
with FN was reflected in our expert opinion survey on
the burden of FN treatment (intravenous antibiotics
were the most frequently prescribed medication in case
of FN). In addition, both oncologists and hematologists
mentioned potential benefits of prophylaxis on hospitali-
zations frequency and duration: they considered both
the number of hospitalizations and the length of hospi-
talization in patients who developed FN to be halved by
G-CSF prophylaxis compared with no prophylaxis.
These potential reductions in length of hospitalization
and hospitalization rates can have a positive impact on
patient’s quality of life and on treatment cost [23,24].
Another notable finding of our study is that dose-
dense or TAC regimens were used in none of the
patients with breast cancer and in fewer than 30% of
patients with NHL. A possible explanation for this find-
ing is that these highly myelotoxic regimens require, for
safe use, upfront prophylaxis against FN, but at the time
the survey was carried out primary prophylaxis was not
covered by Belgian health insurance agencies for
patients aged <65 years.
The main limitations of our study were linked to its
design. Participants had to report patient data them-
selves and therefore the numbers of selected patients
and the list of targeted variables were both limited. In
addition, some centers easily reached the maximum
sample size permitted by the protocol and reported on
only a random selection of their eligible patients,
whereas other centers could include all eligible patients.
As a consequence, a certain selection bias cannot be
excluded.
One consequence of this is that extrapolation of our
results, especially with the small NHL sample, to a gen-
eral population should be attempted with caution (e.g.
by checking the repartition of population by disease
stage). The variability in incidence of neutropenic events
or proportion of patients receiving prophylaxis in the
NHL sample is also higher than in the breast cancer
sample, which could hinder comparison.
In addition, the use of antibiotics reported in the sur-
vey could not be investigated sufficiently in depth in
order to adjust for FN/PSN incidence following antibio-
tic prophylaxis, which is known to reduce the risk of
neutropenic events. However, antibiotic prophylaxis is
not recommended by EORTC guidelines because it can
potentially lead to the emergence of resistance [25].
Finally, a number of queries had to be dealt with
a posteriori to clarify uncertainties regarding the defini-
tions of prophylaxis or the timing of FN occurrence.
Despite the above-mentioned limitations, the out-
comes of this study provided real-life data on incidence
and consequences of FN in these patient groups, and
were subsequently submitted to the Belgian reimburse-
ment commission as part of a request to extend the cov-
erage of primary prophylaxis with pegfilgrastim. As a
result, a reimbursement extension for a subgroup of
high-risk patients with breast cancer and NHL aged
<65 years was granted in September 2009, thereby
improving access to FN prevention with G-CSF for part
of the population targeted by this survey.
Conclusions
The collection of real-life data allowed the identification
of a gap between clinical practice and current recom-
mendations for G-CSF use according to international
guidelines. Our results show that, considering the
observed consequences of FN on chemotherapy delivery
(dose adjustments, delays, dropped cycles), and the
known associated negative impact of such consequences
on the efficacy of treatment, patients with breast cancer
and NHL who are to receive moderate or high risk che-
motherapy regimens may benefit from better access to
primary prophylaxis with G-CSF.
List of abbreviations used
AC-T: anthracyclines, cyclophosphamide followed by docetaxel; ACVBP:
doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone; ASCO:
American society of clinical oncology; BVAM: carmustine, vincristine,
cytarabine, methotrexate; CHOP-21: cyclophosphamide, doxorubicin,
vincristine, prednisone every 21 days; EORTC: European organization for
research and treatment for cancer; ESHAP: etoposide, methylprednisolone,
cytarabine, cisplatin; ESMO: European society for medical oncology; FEC: 5-
fluorouracil/cyclophosphamide/epirubicin; FEC-T: 5-fluorouracil/
cyclophosphamide/epirubicin followed by docetaxel; FN: febrile neutropenia;
G-CSF: granulocyte-colony stimulating factor; HR: hazard ratio; Hyper CVAD:
cyclophosphamide, doxorubicin, vincristine, dexamethasone, methotrexate,
cytarabine; IPI: international prognostic index; NCCN: national comprehensive
cancer network; NHL: non-Hodgkin’s lymphoma; PP: primary G-CSF
prophylaxis; PSN: prolonged severe neutropenia; R: rituximab; R-ACVBP-14:
rituximab with doxorubicin, cyclophosphamide, vindesine, bleomycin,
prednisone for 14 days; R-CHOP-14: rituximab with cyclophosphamide,
doxorubicin, vincristine, prednisone every 14 days; R-CHOP-21: rituximab
with cyclophosphamide, doxorubicin, vincristine, prednisone every 21 days;
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R-COPADEM: rituximab with cyclophosphamide, vincristine, prednisone,
doxorubicin, methotrexate; R-DHAP: rituximab with cisplatin, cytarabine,
dexamethasone; R-GEMOX: rituximab with gemcitabine, oxaliplatin,
prednisone; R-ICE: rituximab with etoposide, carboplatin, ifosfamide; RR:
relative risk; SP: secondary G-CSF prophylaxis (any type); SP-FN: secondary G-
CSF prophylaxis after febrile neutropenia; SP-PSN: secondary G-CSF
prophylaxis after prolonged severe neutropenia; TAC: docetaxel, doxorubicin,
cyclophosphamide.
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